[ ⁸⁹ Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.

Autor: Shuch B; Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: bshuch@mednet.ucla.edu., Pantuck AJ; Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA., Bernhard JC; Department of Urology, Centre Hospitalier Universitaire de Bordeaux-Groupe Hospitalier Pellegrin, Bordeaux, France., Morris MA; United Theranostics, Glen Burnie, Baltimore, MD, USA., Master V; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Scott AM; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., van Praet C; Department of Urology, Ghent University Hospital, Ghent, Belgium., Bailly C; Department of Nuclear Medicine, Nantes University Hospital, Nantes, France., Önal B; Department of Urology, Istanbul University-Cerrahpasa, Istanbul, Turkey., Aksoy T; Department of Nuclear Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey., Merkx R; Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands., Schuster DM; Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA., Lee ST; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Pandit-Taskar N; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA., Fan AC; Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA., Allman P; Premier Research, Morrisville, NC, USA., Schmidt K; ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft, Dresden, Germany., Tauchmanova L; Telix Pharmaceuticals, Melbourne, VIC, Australia., Wheatcroft M; Telix Pharmaceuticals, Melbourne, VIC, Australia., Behrenbruch C; Telix Pharmaceuticals, Melbourne, VIC, Australia., Hayward CRW; Telix Pharmaceuticals, Melbourne, VIC, Australia., Mulders P; Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Oct; Vol. 25 (10), pp. 1277-1287. Date of Electronic Publication: 2024 Sep 10.